Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.

ABSTRACT:

Purpose

Stress-induced adrenergic signaling can suppress the immune system. In animal models, pharmacological beta-blockade stimulates CD8 + T-cell activity and improves clinical activity of immune checkpoint blockade (ICB) in inhibiting tumor growth. Herein, we investigated the effect of BB on clinical outcomes of patients receiving ICB in advanced solid tumors.

Methods

We retrospectively evaluated patients with solid tumors treated with ICB at our institution from January 1, 2011 to April 28, 2017. The primary clinical outcome was disease control. Secondary clinical outcomes were overall survival (OS), and duration of therapy (DoT). The primary predictor was use of BB. Association between disease control status and BB use was assessed in univariable and multivariable logis

SUBMITTER: Mellgard G 

PROVIDER: S-EPMC10739778 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature